GLP-1 compounding regulation

FDA 503B bulks list proposal for semaglutide, tirzepatide, and liraglutide: patient checklist

A clinician-safe Peptide12 guide to the FDA 503B bulks list proposal for semaglutide, tirzepatide, and liraglutide, including what it may mean for GLP-1 pharmacy sourcing, compounded-drug claims, and patient questions.

Educational guideUpdated June 13, 2026

How to read the 503B GLP-1 proposal

1

Confirm the pathway: the FDA proposal addresses the 503B bulks list for outsourcing facilities, not a personal eligibility rule for every patient.

2

Separate FDA-approved branded products from compounded prescriptions. Compounded semaglutide, tirzepatide, or liraglutide are not FDA-approved finished drug products.

3

Ask whether the exact product is Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza, a patient-specific compounded prescription, or an unsafe research-use product.

4

Verify the licensed clinician, dispensing pharmacy or manufacturer channel, label, storage instructions, side-effect plan, and refill pathway before payment or shipment.

5

Avoid sellers that cite 503B, bulk API, COAs, shortage language, or “generic GLP-1” wording to bypass prescriptions, hide sourcing, or imply FDA approval.

Direct answer

FDA has proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, saying it did not identify a clinical need for outsourcing facilities to compound these drugs from bulk substances. That proposal is about one federal outsourcing-facility pathway; it is not a patient-specific prescription decision, not an approval of compounded GLP-1 products, and not a substitute for clinician and pharmacy review.

What FDA proposed

The proposal focuses on 503B outsourcing facilities using bulk drug substances

FDA announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list after reviewing nominations and stating that it did not identify a clinical need for outsourcing facilities to compound these drugs from bulk substances. In plain language, that means patients should be cautious when a seller uses “503B” or “bulk API” language to make compounded GLP-1 access sound routine, permanent, or FDA-approved.

  • 503B outsourcing facilities are a specific federal compounding category; they are not the same as every local or patient-specific pharmacy scenario.
  • FDA-approved GLP-1 products such as Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, and Victoza have official labels for specific uses.
  • A proposed FDA action can change after comments and final agency review, so patients should verify current status from FDA or a licensed clinician rather than relying on ads.

What it does not mean

It is not a shortcut to choose or reject treatment by yourself

The 503B bulks-list proposal does not tell an individual patient whether semaglutide, tirzepatide, liraglutide, another medication, lifestyle care, or no medication is appropriate. That decision still depends on diagnosis, contraindications, pregnancy or fertility plans, diabetes medicines, kidney or gallbladder history, prior side effects, cost, access, and follow-up. It also does not make compounded GLP-1 products FDA-approved finished drugs.

  • Patients should ask whether a compounded option is being discussed because an FDA-approved product cannot meet a documented medical need.
  • Patients should not use research-use peptides, imported bulk powder, or no-prescription GLP-1 products for human treatment.
  • If a seller says the FDA proposal proves its product is allowed, banned, equivalent, or “FDA-approved,” ask for a clinician explanation and official source.

Patient safety questions

The practical impact is pharmacy-source transparency

For patients, the safer response is not to memorize every compounding statute. It is to ask clearer questions before starting or refilling GLP-1 therapy: exact active ingredient, product status, prescriber, pharmacy source, label, storage, dose-change support, side-effect escalation, and whether a branded product, insurance pathway, cash-pay option, or no medication is safer for the situation.

  • Ask whether the prescription is for an FDA-approved branded medication, an individualized compounded prescription, or something the clinician will not prescribe.
  • Ask how the clinic handles warm packages, changed labels, dosing confusion, nausea, vomiting, abdominal pain, dehydration, low blood sugar, pregnancy plans, surgery, or missed refills.
  • Avoid checkout flows that hide the pharmacy, promise guaranteed weight loss, use dosing calculators before review, or treat supply-chain news as marketing urgency.

Patient safety checklist

Questions to ask about GLP-1 compounding and 503B claims

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Is the medication being discussed semaglutide, tirzepatide, liraglutide, Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza, or a compounded prescription?

✓

Is the product FDA-approved for my condition, prescribed off-label, compounded for an individualized need, or not appropriate for online prescribing?

✓

Which licensed clinician reviews my history, and which pharmacy or manufacturer channel dispenses the medication if prescribed?

✓

If a compounded GLP-1 is mentioned, what patient-specific need is being documented, and how is the clinic avoiding claims that the finished compounded drug is FDA-approved?

✓

Does the label clearly show active ingredient, route, concentration or strength, directions, storage instructions, beyond-use or expiration date, pharmacy information, and prescriber information?

✓

How are side effects, dosing confusion, missed doses, refills, product switches, abnormal labs, pregnancy plans, surgery, dehydration, and urgent symptoms handled?

✓

Has the seller used 503B, bulk API, shortage, COA, “generic,” or research-use language to pressure a purchase before clinician and pharmacy review?

✓

Where can I verify the current FDA status, shortage status, and prescribing information before relying on a marketing claim?

FAQs

Short answers for patients

What is the FDA 503B bulks list proposal for GLP-1 drugs?

FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list after saying it did not identify a clinical need for outsourcing facilities to compound those drugs from bulk substances. Patients should treat it as a regulatory sourcing issue, not personal medical advice.

Does the 503B proposal ban all compounded GLP-1 prescriptions?

The proposal is focused on the 503B outsourcing-facility bulks-list pathway. It should not be simplified into “all compounding is banned” or “all compounding is allowed.” Patient-specific questions require clinician, pharmacy, and current FDA-status review.

Are compounded semaglutide or tirzepatide FDA-approved?

No. Semaglutide and tirzepatide are active ingredients in FDA-approved branded medications, but compounded versions are not FDA-approved finished drug products. A clinician should explain the product status, source, reason for compounding, and alternatives.

Should I switch from a compounded GLP-1 because of the proposal?

Do not stop, switch, restart, stretch, or change a GLP-1 medication based only on a headline. Ask the prescribing clinician about current FDA status, branded access, pharmacy sourcing, side effects, refill timing, and whether an individualized prescription still makes sense.

What GLP-1 pharmacy claims are red flags?

Red flags include no-prescription GLP-1 sales, research-use vials for people, hidden pharmacy sourcing, “generic Wegovy” or “generic Zepbound” claims, dosing calculators before clinician review, FDA-approved compounded-drug wording, and marketing that uses 503B or shortage news as pressure.

Where should patients verify GLP-1 regulatory claims?

Use official FDA pages, Federal Register notices, DailyMed or FDA-approved prescribing information, the prescribing clinician, and the dispensing pharmacy. Ads, forums, influencer scripts, and seller-written COAs are not enough to establish safe access.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

FDA: FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks listFederal Register: List of bulk drug substances for which there is a clinical need under section 503BFDA: FDA's concerns with unapproved GLP-1 drugs used for weight lossFDA: Compounding and FDA questions and answersFDA: Drug shortagesDailyMed: Wegovy prescribing informationDailyMed: Zepbound prescribing informationPeptide12: FDA July 2026 peptide compounding meetingPeptide12: GLP-1 shortage status checkPeptide12: 503A vs 503B compounding pharmacyPeptide12: Compounded vs branded peptide medicationsPeptide12: Peptide pharmacy quality checklistPeptide12: Fake GLP-1 online pharmacy checklistPeptide12: Wegovy vs compounded semaglutidePeptide12: Zepbound vs compounded tirzepatidePeptide12: Semaglutide salt formsPeptide12: GLP-1 lab work before therapyPeptide12: GLP-1 prior authorization questionsPeptide12: How online peptide therapy works